0001562180-18-002514.txt : 20180516
0001562180-18-002514.hdr.sgml : 20180516
20180516133747
ACCESSION NUMBER: 0001562180-18-002514
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180515
FILED AS OF DATE: 20180516
DATE AS OF CHANGE: 20180516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Malik Rajesh
CENTRAL INDEX KEY: 0001706853
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38096
FILM NUMBER: 18839524
MAIL ADDRESS:
STREET 1: 79 TW ALEXANDER DRIVE
STREET 2: 4501 RESEARCH COMMONS, SUITE 100
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: G1 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001560241
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263648180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 79 T.W. ALEXANDER DRIVE
STREET 2: 4501 RESEARCH COMMONS, SUITE 100
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-213-9835
MAIL ADDRESS:
STREET 1: P. O. BOX # 110341
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: G-Zero Therapeutics, Inc.
DATE OF NAME CHANGE: 20121012
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2018-05-15
false
0001560241
G1 Therapeutics, Inc.
GTHX
0001706853
Malik Rajesh
C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR.
4501 RESEARCH COMMONS, SUITE 100
RESEARCH TRIANGLE PARK
NC
27709
false
true
false
false
Ch. Medical Officer & SVP R&D
Common Stock
2018-05-15
4
M
false
3776.00
4.17
A
7976.00
D
Common Stock
2018-05-15
4
S
false
3676.00
46.2879
D
4300.00
D
Common Stock
2018-05-15
4
S
false
100.00
46.67
D
4200.00
D
Stock Options (Right to Buy)
4.17
2018-05-15
4
M
false
3776.00
0.00
D
2026-05-10
Common Stock
3776.00
91951.00
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
The price represents the weighted average price with a low of $45.67 and a high of $46.65. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
The shares underlying this option vested as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
/s/ Peter N. Cunningham, attorney-in-fact
2018-05-16